PARSIPPANY, N.J., March 17, 2017 /PRNewswire/ — Onkos Surgical, an innovative surgical oncology company, has announced today it has partnered with the Musculoskeletal Tumor Society (MSTS) as a 2017 Diamond Level Corporate Sponsor.

«Onkos Surgical is investing heavily in research and development to bring meaningful innovation to the surgical oncology space,» said Patrick Treacy, Onkos Co-founder and CEO.  «There are many unsolved clinical challenges like aseptic loosening, infection and soft tissue attachment that our company is focused on.  Our sponsorship of the MSTS is another strong signal that Onkos is committed and aligned to the MSTS mission of advancing the science of orthopaedic oncology and promoting high standards of patient care through excellence in education and research.» Treacy said, «we are honored to support the MSTS and partner with their membership to further innovation for a patient population that deserves better than the standard quo.»

«The MSTS is pleased to partner with Onkos Surgical at the Diamond Level.  Advances in the surgical management of our orthopaedic oncology patients are best accomplished through partnerships between innovative companies and clinicians.  The mission of our organization cannot be realized without the generous support of our sponsors,» said Robert Quinn, MD, President of MSTS.

About Onkos Surgical
Based in Parsippany, NJ., Onkos Surgical is a privately held surgical oncology company founded in 2015. Onkos Surgical believes surgical oncology deserves attention, focus and innovation. Through dedication and strategic partnerships, Onkos Surgical will advance surgical oncology solutions and will advocate for and support the surgeons and caregivers that dedicate their lives to the surgical treatment of cancer.

For more information, visit

About MSTS
The MSTS is a non-profit professional organization comprised of orthopaedic oncologists in North America.  The mission of the society is to advance the science of orthopaedic oncology and promote high standards of patient care through excellence in education and research.  The vision is to be the recognized authority on all aspects of orthopaedic oncology, an influential participant in policy-making for orthopaedic oncology services, and responsive to the needs of orthopaedic oncologists and their patients.

For more information, visit

Investor contacts
Brad Tyler
Senior Vice President, Finance & Administration
[email protected]
(973) 264-5413

To view the original version on PR Newswire, visit:

SOURCE Onkos Surgical